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INTRODUCTION
Breast carcinoma has been dominated disorder in female, whereas 
breast carcinoma in male is relatively rare accounting for about 1% 
of all breast cancers [1]. The mean age at diagnosis for men with 
breast cancer is older than the average age at diagnosis for women 
[2]. Several risk factors have been identified, such as genetic and 
hormonal abnormalities. We present the case of a 29-year-old man 
with invasive ductal breast carcinoma, this is the report of the 
youngest male breast cancer we had experienced.
CASE REPORT
A 29-year-old Korean man was referred to our institution com-
plaining of progressively enlarging his right breast lump. He had 
no significant past medical or family history. He was not taking 
any medication. He was unmarried, but reported normal sexual 
life and did military service as usual manner. He did not drink al-
cohol and had a smoking history of 5 pack years. Physical exam-
ination revealed 2.5 cm round mass in lower inner quadrant of 
right breast. He was an obese person with body mass index (BMI) 
of 30.4 kg/m2. He had the normal testis volume.
Mammography revealed a 3 cm microlobulated, irregular 
high-density mass at right subareola (Fig. 1). On ultrasonography, 
the irregular mass at right subareola was measured 4.19 cm in di-
ameter. The mass had the complex solid and cystic echo pattern 
with posterior enhancement. The margin of mass was not circum-
scribed and a long axis of the mass was parallel to the skin. Ultraso-
nography also showed a suspicious enlarged lymph node at right 
axilla measured 1.31 cm in diameter (Fig. 2). The irregular subare-
olar mass was classified as Breast Imaging-Reporting and Data 
System category 5 and diagnosed as invasive ductal carcinoma 
with fine needle aspiration biopsy. There was no systemic meta-
static evidence on positron emission tomography-computed to-
mography (Fig. 3).
The serum study showed elevated carcinoembryonic antigen 
(7.44 ng/mL) and hemoglobin A1c (8.9%) level and showed nor-
mal cancer antigen 15-3 (15 U/mL), estradiol (21.27 pg/mL) and 
testosterone (7.42 ng/mL) level. Genetic analysis was confirmed as 
eukaryote without chromosomal abnormality and no mutations 
of BRCA 1/2 genes.
He underwent modified radical mastectomy for his breast can-
cer and the final pathologic diagnosis was a 3.6 cm invasive ductal 
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carcinoma with histologic grade 3, nuclear grade 3, estrogen recep-
tor (ER)-positive, progesterone receptor (PR)-negative, human 
epidermal growth factor receptor 2 (HER-2)-positive, and Ki-67 
labeling index of 50%. The axillary lymph node dissection showed 
four positive nodes among 24 lymph nodes retrieved. His final 
stage was IIIA (T2N2M0).
He underwent adjuvant chemotherapy with 6 cycles of 
docetaxel, doxorubicin, and cyclophosphamide. And he also un-
derwent adjuvant radiotherapy, hormonal therapy with daily 
tamoxifen 20 mg, and trastuzumab therapy. Up to now, at 2 years 
after surgery, there was no tumor recurrence.
A B
Fig. 1. Mammogram showed a 3 cm microlobulated, irregular 
high-density mass (arrows) at right subareola. (A) Craniocaudal 
view. (B) Mediolateral oblique view.
Fig. 2. On ultrasonography, (A) the irregular mass at right subareola was measured 4.19 cm in diameter and (B) a suspicious enlarged lymph 
node at right axilla was measured 1.31 cm in diameter. 
A B
Fig. 3. Positron emission tomography-computed tomography scan 
showed abnormal fluorodeoxyglucose uptakes in right subareolar 
breast (arrow) and in right level I axilla (arrowhead). There was no 
other metastatic evidence.
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DISCUSSION
The etiology of male breast cancer is poorly understood, partly be-
cause of its relative rarity. But several risk factors have been identi-
fied, such as genetic and hormonal abnormalities. 
Approximately 15% to 20% of men with breast cancer report a 
family history of breast or ovarian cancer [2]. It is estimated that 
approximately 10% of men with breast cancer have a genetic pre-
disposition, and BRCA2 is the most clearly associated gene muta-
tion [3]. BRCA1 mutation is also associated with male breast can-
cer [4], and associations have also been suggested for CHEK2 mu-
tation [5]. Klinefelter’s syndrome (XXY) has been described in the 
literature as occurring in 3% to 7.5% of men with breast cancer [6]. 
Men with breast cancer should be considered for genetic counsel-
ing and testing, and an adequate family history should be obtained. 
But in this case, the patient had no chromosomal abnormality and 
no mutation of BRCA 1/2.
Estrogen excess and lack of androgens contribute to several con-
ditions associated to the risk of male breast cancer [2]. Men with 
Klinefelter’s syndrome present testicular dysgenesis, gynecomas-
tia, low testosterone concentrations, and increased gonadotro-
phins [2,6]. But this patient had no hormonal abnormality and had 
normal testis volume.
It is documented the association of obesity and male breast can-
cer that is biologically explained by the increased peripheral aro-
matization of estrogen [2]. The American Association of Retired 
Persons Diet and Health Study Cohort identied obesity as a risk 
factor for male breast cancer [7]. Men with BMI of ≥ 30 kg/m2 had 
an 80% increased risk of breast cancer compared with men with 
BMI of less than 25 kg/m2. In this case, the patient was obese per-
son with BMI of 30.4 kg/m2. So, his obesity may contribute to his 
breast cancer.
Some studies found slightly elevated risk of male breast cancer 
associated with a history of diabetes. A history of diabetes was re-
lated to a modest but statistically significant risk increase [8]. So, 
his diabetes may contribute to his breast cancer. 
Type 2 diabetes has been suggested to increase risk of female 
breast cancer. Hyperinsulinemia, as occurs in adult-onset diabetes, 
may promote breast cancer because insulin may be a growth factor 
for human breast cancer cell [9]. However, many studies have 
lacked information about the type and severity of diabetes, making 
the interpretation of various findings difficult. One study showed 
that female breast cancer with type 2 diabetes had a higher expres-
sion of the insulin-like growth factor 1 receptor (IGF1R), and the 
higher IGF1R was associated with negative human epidermal 
growth factor receptor 2 (HER-2) expression [10]. However, some 
study showed that expression patterns of growth factor receptors 
and membrane proteins in male breast cancer are different from 
female breast cancer [11].
Alcohol consumption has not been consistently identied as a 
risk factor for male breast cancer. In a case-control study involving 
74 male breast cancers and 1,432 controls, the risk of breast cancer 
increased 16% per 10 g daily alcohol intake [2,12]. But this patient 
did not drink alcohol.
Epidemiologic studies of male breast cancer are uncommon, 
and most to date have been small case–control studies, raising the 
possibility that identified risk factors could reflect the influence of 
chance or selection and recall biases [8]. There is still a paucity of 
randomized controlled trials and treatment for male breast cancer 
is based on treatment for female breast cancer. As in women, men 
with localized and operable breast cancer are treated with locore-
gional therapy with surgery plus or minus radiation and systemic 
therapy with endocrine therapy, chemotherapy, and HER 2-direct-
ed therapies. Traditionally, the preferred surgical approach was a 
modified radical mastectomy. Breast conserving therapy is a possi-
ble option for men with breast cancer. However, the lack of ade-
quate surrounding breast tissue and the central location of tumors 
precludes this approach in some. Recently, there has been an in-
crease in the incidence of male breast cancer, along with the in-
crease in female breast cancer. Further research in the understand-
ing of male breast cancer is warranted to better guide treatment 
decision-making in these patients.
At the 37th San Antonio Breast Cancer Symposium, Dr Fatima 
Cardoso from Champalimaud Cancer Centre, Lisbon, Portugal 
presented the first results of the EORTC (European Organization 
for Research and Treatment of Cancer) 10085/TBCRC (Transla-
tional Breast Cancer Research Consortium)/BIG (Breast Interna-
tional Group)/NABCG (North American Breast Cancer Groups) 
International Male Breast Cancer Programme [13]. Cardoso and 
colleagues established a retrospective joint analysis of all male 
breast cancers diagnosed within the last 20 years and set up a pro-
spective international registry running over 30 months from 278 
breast centers. The data analysis showed that median age at diag-
nosis for males was 68.4 years and male breast cancer received 
more aggressive surgical intervention (96% of mastectomies and 
76% of axillary clearance). Adjuvant radiotherapy was mostly cor-
rectly provided, but still 36% of N1 and 15% of N2 patients did not 
receive it. Male breast cancer presents usually as luminal A like 
subtype, 88% express androgen receptors, only 1% is triple nega-
tive, and 9% HER-2 positive. A total of 77% of male breast cancer is 
treated by adjuvant endocrine therapy—mainly tamoxifen 
(88%)—and the ER and PR status being prognostic with high ex-
pression associated with better outcomes.
Overall survival of male breast cancer is similar to that of wom-
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en with breast cancer. Similar to women with breast cancer, stage, 
tumor sized, and axillary lymph node status are important factors 
influencing outcome. The impression that male breast cancer has a 
worse prognosis may stem from the tendency toward diagnosis at 
a later stage [2]. Some studies have found the distribution of tumor 
subtypes in male breast cancer to be different compared with fe-
male breast cancer, which may point to important differences in 
biology and outcomes [14].
Now, Advancements in the characterization and genomic map-
ping of male breast cancer have been discussed. It is hoped that 
these huge efforts for rare disease are able to derive more results for 
understanding of male breast cancer.
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